Bioregulators Khavinson bioregulator tripeptideNot FDA-approved · research compound

Crystagen

Crystagen (Khavinson)

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

1 mg daily SubQ 10 day intensive, then 4-6 months off

10-20 mg Oral Daily

Immune system regulatorLymphocyte function modulator

Crystagen (Thr-Glu-Asp) is a Khavinson bioregulator tripeptide targeting the immune system, specifically supporting lymphocyte function and immune cell gene expression. It complements Thymalin (thymus) and Vladonix (thymus gland) by targeting peripheral immune cell function rather than thymic development.

Quick Start

Route

SubQ injection

Start low

1 mg SubQ

Frequency

10 day intensive, then 4-6 months off

Timing

No fasting required

Starting dose. 1 mg — Daily

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

1 mg daily · SubQ injection · 10 day intensive, then 4-6 months off

conservative starter

1 mg daily

10 day intensive, then 4-6 months off

Standard

Immune System Bioregulation (Oral capsule)

10-20 mg · Oral · Daily

anecdotal · community

Synthetic peptide analogous to Vladonix, acting on the thymus to modulate immunity. This is the ORAL capsule dose and is not an injection dose. Oral peptide absorption is poor, so this figure is far higher than the injectable protocol on purpose. Do not inject this amount.

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Crystagen modulates gene expression in lymphocytes and other immune cells, supporting cytokine production, cell proliferation pathways, and immune surveillance function.

What to expect

Early

Days 1–7

Days 1-10: Gene changes initiated.

Mid

Weeks 2–4

Weeks 2-8: Immune gene programs established.

Later

Weeks 4–12

Months: Sustained immune optimization.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Crystagen activated B cells in the aging spleen but did not cause spleen-cell renewal.

Crystagen also activates B-cells of the immune system; however, the peptide doesn't cause cell renewal in spleen as it ages.

[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process]. Advances in gerontology = Uspekhi gerontologii · 2014 · PMID 28976144

Evidence scope. Exact peptide, but a brief aging-spleen study abstract; it does not establish broader human lymphocyte/cytokine mechanisms.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Quick-start dose/route: 1 mg SubQ daily for 10 days. No checked abstract administered Crystagen at this dose or route.

Detailed mechanism: cytokine production, lymphocyte proliferation, and immune surveillance. The exact-name abstract supports only a narrower B-cell finding.

Primary safety: very well tolerated with autoimmune caution. No checked human safety abstract was found. Embedded PMIDs 19830585 and 19902107 are broad peptide-aging reviews; PMID 12937682 is Epithalon, not Crystagen.

The honest take

◆

Immune optimization

Bioregulatory mechanism targeting lymphocyte gene expression.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

◆

Pin alone. Crystagen must not share a syringe with anything else, whatever the pharmacology says. PIN ALONE.

Documented together

TA-1Crystagen bioregulates immune gene expression, TA-1 directly modulates immune effector cells.

ThymalinThymalin targets thymus, Crystagen targets peripheral immune cells. Run in sequence.

Keep separate

GHK-CuCopper degrades bioregulators.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Very well tolerated

Less common & notes

Autoimmune caution.
Excellent safety profile.

Pharmacokinetics

Illustrative plasma concentration · 2.0 h

Half-life

0.5h

Peak · Tmax

0.05h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

Weeks to months (immune gene expression changes persist long after peptide clearance)

Clearance

Rapid enzymatic degradation (peptidases); renal excretion of amino acid components

Storage. Standard BAC water 2-8C. 21-28 days.

Regulatory status

Not FDA-approved. Research peptide.

Put it to work

Calculate, log & track

Open Crystagen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Crystagen in the app →

Go deeper

The guide & community

The complete Crystagen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community